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INTRODUCTION
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous
group of lymphoproliferative malignancies with differing
patterns of responses to treatment (1). A combination chemo-
therapy regimen such as CHOP (cyclophosphamide, doxo-
rubicin, vincristine, and prednisone) is effective for patients
with aggressive NHL, but nearly 50% of patients do not go
into complete remission (CR) and approximately 10% to
20% of patients with CR eventually experience relapses (2).
For those who are refractory to the first-line therapy or relapse
at a later time need additional therapy, but the long-term
prognosis is dismal.
As a new way of cure, high-dose chemotherapy (HDC)
with hematopoietic stem cell transplantation (HSCT) has
become the gold standard as compared to the conventional
salvage therapy (3). However, patients with an old age, poor
performance status, or prior history of chemotherapy resis-
tance are not candidates for this approach, and an effective
salvage regimen for these patients is needed. For patients with
a primary refractory disease, a recent study emphasizes the
importance of chemosensitivity in determining the outcome
of HDC with HSCT (4). It is suggested that patients with
primary refractory aggressive NHL should be treated with
second-line chemotherapy, and HDC with HSCT should be
a treatment option for patients with a chemosensitive disease.
Considering this point, to find an effective salvage regimen
for refractory or relapsed NHL is important. 
ESHAP is a combination chemotherapy regimen consist-
ing of etoposide, methylprednisolone, cytosine arabinoside,
and cisplatin, and its efficacy and feasibility in relapsed or
refractory NHL was reported by Velasquez et al. (5) for the
first time, and followed by others (6, 7). However, few stud-
ies have been reported on the effects of an ESHAP regimen
in Korean patients. To determine the effect and tolerability
of ESHAP chemotherapy as a salvage regimen for the Kore-
an patients, we undertook this retrospective study.
MATERIALS AND METHODS
Eligibility
Between January 1996 and February 2000, 40 patients
who visited the Korea University Anam and Guro Hospital
were enrolled in this study. All patients had evaluable NHL
that was primary refractory or had relapsed after one doxoru-
bicin-based regimen. Inclusion criteria were: histologic diag-
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ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's
Lymphoma
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide,
methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has
been shown to be active against refractory or relapsed non-Hodgkin’s lymphoma
(NHL) in therapeutic trials. We undertook this study to determine whether this regi-
men would be effective and tolerable in Korean patients. A total of 40 patients with
refractory or relapsed NHL (8 indolent and 32 aggressive) were enrolled in this
study. The overall response rate was 70% (95% confidence interval; 59.8-89.7%);
22.5% of patients achieved a complete response and 47.5% a partial response. The
median survival duration was 12 months (95% confidence interval; 5.9-18.1 months)
and the median duration of progression-free survival was 9 months (95% confidence
interval; 1.1-16.9 months). The median survival duration of patients with relapsed
NHL was longer than that of patients with refractory lymphoma (15 months vs 4
months, p=0.02). Myelosuppression was the most frequent complication and treat-
ment-related mortality was noted in two patients. These results suggest that the
ESHAP regimen is effective in patients with relapsed NHL who have a sensitive
disease. The role of ESHAP chemotherapy in discriminating patients who are
more likely to benefit from a subsequent transplant should be evaluated in the
future.  
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nosis of NHL, refractory or relapsing after one or more che-
motherapy regimens; age younger than 75 yr; performance
status less than 2; normal hepatic, renal, and bone marrow
functions; and signed informed consent. They were graded
according to the Ann Arbor classification and international
prognostic index (IPI), and the disease was reclassified accord-
ing to the REAL classification. We only distinguished be-
tween indolent and aggressive forms of lymphoma in the
results and for discussion.
Treatment
The ESHAP regimen consisted of etoposide (40 mg/m2,
days 1-4), methylprednisolone (500 mg, days 1-5), ara-C (2
g/m2, day 5), and cisplatin (25 mg/m2, days 1-4), using its
original schedule with dose modifications (5). Cycles were
repeated every 3-4 weeks, provided that a minimum of 1.0
×109/L absolute neutrophil count (ANC) and 100×109/L
platelets had been reached.
Evaluation
The response to salvage therapy was assessed after a mini-
mum of two courses of chemotherapy. The standard WHO
response criteria were used to assess the response to treatment,
and toxicity was also reported using the WHO criteria. The
response duration was calculated from the date the response
was confirmed to the date the progressive disease was first
observed. Overall survival (OS) was calculated from the first
day of the first cycle of the ESHAP therapy to death or the
last date the patient was known to be alive. Overall survival
curves were plotted with the Kaplan-Meier method.
RESULTS
Patients
A total of 40 patients (36 males and 4 females) aged from
17 to 73 yr (median 43) were enrolled. Patient characteris-
tics are listed in Table 1. Of these patients, 36 (70%) had a
WHO performance status grade 0 or 1 and four patients had
grade 2. Before the first ESHAP cycle, the disease status was
primary refractory in 9 (22.5%) patients, and relapse in 31
(77.5%) patients. Patients with stage II were 17 (42.5%),
and those with stage III and IV were 16 (40%) and 7 (17.5%),
respectively. The histologic type was indolent in 8 (20%)
patients and aggressive in 32 (80%) patients.
Response to ESHAP chemotherapy
The 40 enrolled patients received a total of 154 courses of
treatment; the median number of courses per patient was
3.85, with a range of one to eight. Complete response (CR)
was achieved in 9 (22.5%) patients and partial response (PR)
in 19 (47.5%) patients. Therefore, the overall response rate
was 70% (95% confidence interval; 59.8-89.7%) (Table 2).
Among nine patients with a refractory disease, none attained
CR and four patients achieved PR. The median survival dura-
Number of patients 40
Median age (range) (yr) 43 (17-73)
Male/Female 36/4
WHO performance status
0-1 36 (90)
2 4 (10)
Serum LDH level
Normal 28 (70)
Increased 12 (30)
Disease status
Relapsed 31 (77.5)
Refractory 9 (22.5)
Stage
Stage II 17 (42.5)
Stage III 16 (40.0)
Stage IV 7 (17.5)
Histology
Indolent 8 (20)
Aggressive 32 (80)
IPI risk group
Low 17 (42.5)
Low-intermediate 14 (35.0)
High-intermediate 5 (12.5)
High 4 (10.0)
Characteristics No (%)
Table 1. Patient characteristics
LDH; lactate dehydrogenase. IPI; international prognostic index.
No. of patients 40 
Response (%)
Complete response 9 (22.5)
Partial response 19 (47.5)
Stable disease 5 (12.5)
Progressive disease 7 (17.5)
Total treatment cycles 154
Median 4
Median duration of survival (months) 12
Range 2-53
Characteristics No. (%)
Table 2. Treatment response in patients with NHL receiving
ESHAP chemotherapy
Neutropenia 65 (42.2) 35 (22.7)
Thrombocytopenia 61 (39.6) 22 (14.3)
Nausea/Vomiting 50 (32.5) 10 (6.5)
Mucositis 23 (14.9) 7 (4.5)
WHO Grade
Table 3. Major toxicities of ESAHP chemotherapy
Number of cycles (%) (n=154)
34tion was 12 months (95% confidence interval; 5.9-18.1
months) and the median duration of progression-free survival
was 9 months (95% confidence interval; 1.1-16.9 months).
We analyzed the survival duration according to the disease
status. As a result, the median survival duration of patients
with relapsed NHL was longer than that of patients with
refractory lymphoma (15 months vs 4 months, p=0.02). We
also analyzed the overall survival and progression-free survival
according to the IPI risk group. The low risk IPI subgroups
(low and low-intermediate) showed longer duration of over-
all survival than the high risk IPI subgroups (high-interme-
diate and high) (median: 15 months vs 6 months, p=0.02)
(Fig. 1). The progression-free survival was also longer in the
low risk subgroups (median: 11 months vs 0 months, p=0.02)
(Fig. 2).
Toxicity
The main toxicities encountered with ESHAP chemothe-
rapy were hematologic toxicities (Table 3). WHO grades 3
and 4 neutropenia was observed in 65 (42.2%) and 35 (22.7
%) cycles, respectively. Grade 3 and 4 thrombocytopenia was
observed in 61 (39.6%) cycles and 22 (14.3%) cycles, respec-
tively. Neutropenic fever was noted in 20 (13%) cycles. Other
side effects were nausea, vomiting, and mucositis. Alopecia
was detected in all patients. Treatment-related death was ob-
served in 2 patients, and all were non-responders to ESHAP
therapy. Sepsis associated with severe neutropenia was the
cause of death.
DISCUSSION
The treatment of choice for patients with an advanced stage
NHL is the combination chemotherapy either alone or fol-
lowed by involved-field radiotherapy (1, 8). Although the
CHOP combination chemotherapy remains the best available
regimen, the outcome of patients who do not attain response
is poor and these patients should be included in phase II tri-
als testing new strategies. The prognosis of partial responders
is also poor, particularly for aggressive lymphomas, with only
0% to 25% of patients becoming long-term survivors (9).
Thus it is clinically important to have an effective and well-
tolerated salvage therapy. Previous studies for recurrent or
refractory NHL involved IMVP-16 (ifosfamide, methotrex-
ate, and etoposide) (10), MIME (methyl-gag, ifosfamide, me-
thotrexate, and etoposide) (11), DHAP (cisplatin, ara-C, and
dexamethasone) (12), and EPOCH (etoposide, vincristine,
doxorubicin, cyclophosphamide, and prednisone) (13). The
IMVP-16 study included NHL patients with various histo-
logic types and the overall CR rate was 37%. Thirty-four
patients had a diffuse large cell lymphoma and their long-
term survival was 20%. The MIME regimen was used to
treat 123 patients with aggressive lymphomas, including
94 with a diffuse large cell histology. The CR rate for the
aggressive histologies was 32% and the survival rate was ap-
proximately 20%. The DHAP study included 90 patients
and 77 had an aggressive histology. Survival rate among the
entire group was approximately 25%. The EPOCH regimen
included 74 patients and 56 patients had an aggressive lym-
phoma. The CR rate was 27%. Thus, the four studies are very
similar in their results.
In our series, we demonstrated that the ESHAP regimen
could achieve an overall response rate of 70% (28/40) in pa-
tients with relapsed or refractory NHL, and this is similar
to the results from the previous ESHAP trials (5-7). How-
ever, none of the 9 patients with a refractory disease attained
CR; 4 patients attained PR and the remaining 5 had a pro-
gressive disease. Among 4 patients with PR, three relapsed
during the follow-up period (duration: 5, 7, and 9 months,
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Fig. 1. Overall survival of relapsed/refractory NHL patients accord-
ing to IPI subgroups. 
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Fig. 2. Progression-free survival of relapsed/refractory NHL patients
according to IPI subgroups.respectively) and only one showed a progression-free survival
(duration: 29 months); therefore, this regimen was not effec-
tive in refractory NHL. The major toxicities were neutrope-
nia and thrombocytopenia and two patients died of sepsis
associated with neutropenia. Although the overall response
rate was high, the duration of progression-free survival was
relatively short (9 months) and the response of the primary
refractory group was poor.
As a new strategy for salvage treatment of lymphoma, high-
dose chemotherapy with autologous bone marrow transplan-
tation (ABMT) is currently used. A successful ABMT was
first reported by Appelbaum et al. (14), and a favorable im-
pact on survival in patients with relapsed NHL was report-
ed by others (15, 16). For primary refractory cases, a recent
study by Kewalramani et al. (4) revealed that there were no
survival differences between the partial responders to induc-
tion and the induction failure group. They concluded that
patients with primary refractory aggressive NHL should re-
ceive second-line chemotherapy, with the intent of adminis-
tering high-dose chemotherapy with ABMT to those with a
chemosensitive disease. To discriminate patients more likely
to benefit from a subsequent transplant, the ESHAP regimen
could be a useful second-line chemotherapy (17). In our series,
six patients have undergone ABMT after ESHAP chemo-
therapy until now (data not shown). We may confirm the
effectiveness of the ESHAP regimen to predict a response to
ABMT in a subsequent study.
In conclusion, ESHAP chemotherapy was effective and
feasible for patients with relapsed NHL. However, in consid-
eration of the short progression-free survival and poor response
in the refractory group, a more effective salvage regimen must
be sought, and the role of ESHAP chemotherapy to discrim-
inate patients who are more likely to benefit from a subse-
quent transplant should be evaluated in the future. 
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